BR112013002641A2 - formulação de micropartículas para administração de medicamentos pulmonares de molécula anti-infeccionais para tratamento de doenças infecciosas - Google Patents
formulação de micropartículas para administração de medicamentos pulmonares de molécula anti-infeccionais para tratamento de doenças infecciosasInfo
- Publication number
- BR112013002641A2 BR112013002641A2 BR112013002641A BR112013002641A BR112013002641A2 BR 112013002641 A2 BR112013002641 A2 BR 112013002641A2 BR 112013002641 A BR112013002641 A BR 112013002641A BR 112013002641 A BR112013002641 A BR 112013002641A BR 112013002641 A2 BR112013002641 A2 BR 112013002641A2
- Authority
- BR
- Brazil
- Prior art keywords
- formulation
- administration
- pulmonary
- microparticles
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
formulação de micropartículas para administração de medicamentos pulmonares de molécula anti-infeccionais para tratamento de doenças infecciosas. a presente invenção refere-se a uma formulação de micropartículas biodegradáveis, inalável contendo um composto de fórmula i obtido por fermentação de um microrganismo da espécie streptomyces (pm626271/mtcc5447), tal como descrito na publicação de pedido pct wo2011027290, e um lípido biodegradáveis para a entrega de drogas, em que o proporção de droga (composto da fórmula i) para lípidos é 1:15 - 1:25. a presente invenção ttambém se relaciona com o processo para preparação da formulação e do método de tratamento da tuberculose pulmonar, tuberculose resistente múltiplos fármacos (mdrtb), resistentes à meticilina staphylococcus aureus (mrsa) e staphylococcus pneumonias staphylococcus aureis sensível (mssa) através da administração de pneumonias quantidade terapeuticamente eficaz da formulação a um mamífero em necessidade deste. a presente invenção diz ainda respeito a um método de entregar a formulação de micropartículas a um método de necessidade deste, em que a formulação é administrada por inalação ou por instilação intratraqueal para entrega pulmonar.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37091610P | 2010-08-05 | 2010-08-05 | |
PCT/IB2011/053470 WO2012017405A1 (en) | 2010-08-05 | 2011-08-04 | Microparticle formulation for pulmonary drug delivery of anti-infective molecule for treatment of infectious diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013002641A2 true BR112013002641A2 (pt) | 2016-06-07 |
Family
ID=44653372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013002641A BR112013002641A2 (pt) | 2010-08-05 | 2011-08-04 | formulação de micropartículas para administração de medicamentos pulmonares de molécula anti-infeccionais para tratamento de doenças infecciosas |
Country Status (14)
Country | Link |
---|---|
US (1) | US8697653B2 (pt) |
EP (1) | EP2600842A1 (pt) |
JP (1) | JP2013532722A (pt) |
KR (1) | KR20130109106A (pt) |
CN (1) | CN103442694B (pt) |
AU (1) | AU2011287205A1 (pt) |
BR (1) | BR112013002641A2 (pt) |
CA (1) | CA2807357A1 (pt) |
IN (1) | IN2013MN00329A (pt) |
MX (1) | MX2013001325A (pt) |
RU (1) | RU2013109384A (pt) |
TW (1) | TW201208716A (pt) |
WO (1) | WO2012017405A1 (pt) |
ZA (1) | ZA201301662B (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015107482A1 (en) * | 2014-01-17 | 2015-07-23 | Piramal Enterprises Limited | Pharmaceutical combination for treatment of tuberculosis |
US10335374B2 (en) | 2014-12-04 | 2019-07-02 | University System of Georgia, Valdosta State University | Tablet composition for anti-tuberculosis antibiotics |
CN109827875A (zh) * | 2019-04-10 | 2019-05-31 | 上海市食品药品检验所 | 一种用于测定吸入制剂溶出度的装置和方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8601457D0 (sv) * | 1986-04-01 | 1986-04-01 | Draco Ab | Compositions of liposomes and b?712-receptor active substances for inhalation |
JPH0751496B2 (ja) * | 1986-04-02 | 1995-06-05 | 武田薬品工業株式会社 | リポソ−ムの製造法 |
TW497974B (en) * | 1996-07-03 | 2002-08-11 | Res Dev Foundation | High dose liposomal aerosol formulations |
CN100358494C (zh) * | 1998-11-12 | 2008-01-02 | 弗兰克G·皮尔基威克兹 | 一种吸入给药系统 |
WO2001054693A1 (en) * | 2000-01-31 | 2001-08-02 | Eisai Co., Ltd. | Use of thiostrepton as an anti-mycobacterial agent |
US20030224039A1 (en) * | 2002-03-05 | 2003-12-04 | Transave, Inc. | Methods for entrapment of bioactive agent in a liposome or lipid complex |
ES2435197T3 (es) * | 2007-01-10 | 2013-12-16 | Board Of Regents, The University Of Texas System | Administración mejorada de composiciones de fármacos inmunosupresores para la administración por vía pulmonar |
US10501492B2 (en) | 2009-09-02 | 2019-12-10 | National Centre For Polar And Ocean Research (Ncpor) | Antibiotic compounds |
-
2011
- 2011-08-04 RU RU2013109384/15A patent/RU2013109384A/ru not_active Application Discontinuation
- 2011-08-04 AU AU2011287205A patent/AU2011287205A1/en not_active Abandoned
- 2011-08-04 CN CN201180043763.9A patent/CN103442694B/zh not_active Expired - Fee Related
- 2011-08-04 KR KR1020137005739A patent/KR20130109106A/ko not_active Application Discontinuation
- 2011-08-04 EP EP11757941.7A patent/EP2600842A1/en not_active Withdrawn
- 2011-08-04 JP JP2013522337A patent/JP2013532722A/ja active Pending
- 2011-08-04 US US13/813,470 patent/US8697653B2/en active Active
- 2011-08-04 CA CA2807357A patent/CA2807357A1/en not_active Abandoned
- 2011-08-04 MX MX2013001325A patent/MX2013001325A/es active IP Right Grant
- 2011-08-04 TW TW100127712A patent/TW201208716A/zh unknown
- 2011-08-04 BR BR112013002641A patent/BR112013002641A2/pt not_active IP Right Cessation
- 2011-08-04 IN IN329MUN2013 patent/IN2013MN00329A/en unknown
- 2011-08-04 WO PCT/IB2011/053470 patent/WO2012017405A1/en active Application Filing
-
2013
- 2013-03-05 ZA ZA2013/01662A patent/ZA201301662B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2011287205A1 (en) | 2013-03-07 |
EP2600842A1 (en) | 2013-06-12 |
WO2012017405A1 (en) | 2012-02-09 |
IN2013MN00329A (pt) | 2015-05-29 |
CN103442694A (zh) | 2013-12-11 |
JP2013532722A (ja) | 2013-08-19 |
CA2807357A1 (en) | 2012-02-09 |
US20130125879A1 (en) | 2013-05-23 |
KR20130109106A (ko) | 2013-10-07 |
US8697653B2 (en) | 2014-04-15 |
MX2013001325A (es) | 2013-10-28 |
TW201208716A (en) | 2012-03-01 |
CN103442694B (zh) | 2015-09-09 |
RU2013109384A (ru) | 2014-09-10 |
ZA201301662B (en) | 2014-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bassetti et al. | Inhaled liposomal antimicrobial delivery in lung infections | |
BR112015012351A8 (pt) | composição de antibiótico de glicopeptídeo à base de lipídeo estabilizado e uso de um componente lipídico, um componente de antibiótico de glicopeptídeo e um aminoácido ou derivado do mesmo | |
Suh et al. | Biofilms | |
BR112014029010A2 (pt) | sistemas para tratamento de infecções pulmonares | |
MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
US20230124862A1 (en) | Bismuth thiol compounds and compositions and methods of treating microbial co-infections | |
CN109549925B (zh) | 用于治疗细菌感染的定制脂质体 | |
GT201400016A (es) | Indazoles | |
BR112018010962A2 (pt) | composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratar uma infecção bacteriana, e, uso de um composto. | |
BR112014011841A2 (pt) | material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos | |
BR112015009913A2 (pt) | composições farmacêuticas para o tratamento de doenças mediadas por cftr | |
BR112014010291A2 (pt) | composições de lipossoma combinacionais para terapia de câncer | |
BR112015005940A2 (pt) | processo para a preparação de nanopartículas terapêuticas | |
BR112013011580A2 (pt) | derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep | |
BR112014026212A8 (pt) | equipamento para administração de medicamento, processo para administração de um medicamento e uso de um equipamento para administração de medicamento | |
BR112018067930A2 (pt) | composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratamento de uma infecção bacteriana, e, uso de um composto. | |
BR112013002641A2 (pt) | formulação de micropartículas para administração de medicamentos pulmonares de molécula anti-infeccionais para tratamento de doenças infecciosas | |
BR112015007647A2 (pt) | derivados de quetamina | |
BRPI0915942A2 (pt) | método para produção de compostos medicinais contendo dabigatrana | |
BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
BR112017020039A2 (pt) | composição farmacêutica, kit, método, processo para preparar uma composição e solução farmacêutica | |
BR112022014578A2 (pt) | Composição e métodos de profiláticos e terapêuticos de rnai para o tratamento de infecção respiratória aguda grave causada pelo novo coronavírus 2019 (2019-ncov) | |
Van Westreenen et al. | New antimicrobial strategies in cystic fibrosis | |
Schwarz | Colobreathe® for the treatment of cystic fibrosis-associated pulmonary infections | |
GB2577419A (en) | Lipo-glycopeptide cleavable derivatives and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A ANUIDADE |
|
B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |